“What Happens Next?”: Psychedelic Renaissance

Monash Lens

Attitudes towards psychoactive drugs for the treatment of mental health are changing, and for good reason – it’s hard to disagree with the evidence of the therapeutic benefits. Compelling studies are being conducted around the world, several of them here at Monash. And it won’t be long until you see the results of these studies for yourself – experts suggest health care providers could begin prescribing psychedelic drugs for PTSD patients as soon as 2023.

  • Susan Carland

    Academic, author and social commentator

  • Paul Liknaitzky

    Research Fellow, Psychiatry Monash Health

  • Meaghan O’Donnell

    Head of Research, Phoenix Australia

In this episode of “What Happens Next?”, Dr Susan Carland talks to Dr Paul Liknaitzky, the principal investigator on a number of Australia’s first clinical psychedelic trials. She’s also joined by Dr Meaghan O’Donnell, head of research at Phoenix Australia, the centre for posttraumatic mental health, and professor in the Department of Psychiatry at the University of Melbourne.

Listen now to learn how psychedelic drugs, in concert with more traditional therapies, can help trauma survivors shift their perceptions, and about some of the upcoming research that will revolutionise psychiatry and change the lives of millions of people suffering from mental illness.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.